A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug R&D using artificial intelligence, the group exclusively told Endpoints News.
The company, Xaira Therapeutics, is one of this year’s most richly funded new companies, not only in biotech but across the startup world, reflecting the enthusiasm and technological progress in using AI to unlock the mysteries of biology. The group has tapped Marc Tessier-Lavigne, formerly the president of Stanford University and chief scientific officer of Genentech, as CEO to turn a cash-flush vision into reality.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.